In fact, sublethal taxol, doxorubicin, cisplatin, and gemcitabine treatments that resulted in elevated cellular migration, invasion, and metastasis in NSCLC (Figure 2, Table 1) echoed an early finding in breast cancer where sublethal doxorubicin promoted migration and invasion via the regulation of Src family kinases [15]. Here, SRC is linked to breast cancer.